Eisai Inc.
100 Tice Boulevard
Woodcliff Lake
New Jersey
07677
U.S.A.
Phone:
201-692-1100
Fax:
201-692-1804
|
Eisai Inc. is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops, and markets products throughout the world. Eisai’s worldwide hhc mission is to satisfy unmet medical needs and contribute to the health and well-being of people worldwide.
Established in 1995 and ranked among the top 20 U.S. pharmaceutical companies (based on retail sales), Eisai Inc. began marketing its first product, Aricept® (donepezil hydrochloride tablets), in 1997. Since then, the company has rapidly grown to become an integrated pharmaceutical business that is capable of developing, manufacturing, distributing and marketing high-quality products independently or in collaboration with others. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care.
Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. employs approximately 1,900 people in the United States. The company’s state-of-the-art pharmaceutical production and formulation research and development operations are based in Research Triangle Park, North Carolina. The company also has a production facility in Baltimore, Maryland.
Over the past six years, Eisai has completed a number of significant in-licensing and acquisition transactions. Most recently, these include the acquisitions of Morphotek, Inc. and MGI PHARMA, INC.
Morphotek was acquired in 2007 and is a biopharmaceutical R&D company focused on the discovery and development of therapeutic monoclonal antibodies for use in the treatment of cancer, as well as inflammatory and infectious diseases. Its monoclonal antibody expertise and existing therapeutic focus enhances Eisai’s well-established small molecule R&D capabilities.
MGI PHARMA, INC. was acquired in 2008 and is a biopharmaceutical company focused in oncology and acute care. Together with Eisai’s existing oncology product portfolio, global infrastructure and innovation capabilities, this acquisition has expanded Eisai’s R&D and commercial capabilities.
Moving forward, Eisai's goal is to continue to discover, develop and seek specialty products that support our human health care (hhc) mission.
Contact Information:
For more information about Eisai Inc., including press releases and career opportunities, please visit www.eisai.com.
Email:
Ownership:
Web Site:
Eisai Inc.
Employees:
Approximately 1,900
Symbol: ESALF.PK
|